INmune Bio News

Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB), Insmed (INSM) and Tenet Healthcare (THC)

TipRanksMay 14 07:50 ET

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

Yahoo FinanceMay 12 09:28 ET

Robust Pipeline and Financial Stability Underpin Buy Rating for Inmune Bio

TipRanksMay 11 12:35 ET

INmune Bio | 10-Q: Quarterly report

Futu NewsMay 9 17:14 ET · Announcements

INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate

INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36)

BenzingaMay 9 16:57 ET

Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000

04:21 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000

MT NewswiresMay 9 16:21 ET

Express News | INmune Bio Q1 Operating Expenses USD 11.031 Million

ReutersMay 9 16:05 ET

Express News | INmune Bio Q1 Basic EPS USD -0.61

ReutersMay 9 16:05 ET

Express News | INmune Bio Q1 Operating Income USD -11.017 Million

ReutersMay 9 16:05 ET

Express News | INmune Bio Q1 Revenue USD 14 Thousand

ReutersMay 9 16:05 ET

Express News | INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

ReutersMay 9 16:05 ET

INmune Bio 1Q Loss/Shr 61c >INMB

INmune Bio 1Q Loss/Shr 61c >INMB

Dow JonesMay 9 16:05 ET

Express News | INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

ReutersMay 7 08:00 ET

Express News | INmune Bio Inc Files for Mixed Shelf Offering of up to $250 Mln - SEC Filing

ReutersMay 1 16:06 ET

Inmune Bio's Promising INKmune Therapy and Strong Financials Merit a Buy Rating

TipRanksApr 30 13:45 ET

Express News | INmune Bio Provides Update On Two Patients From Phase 1b Alzheimer's Disease Trial Receiving XPro Under Compassionate Use; Says 'Reports From the Primary Care Physicians Indicate That XPro Has Been Well-tolerated Throughout the Treatment Period, With Stab

BenzingaApr 30 08:06 ET

Express News | INmune Bio Inc: According to Primary Care Physicians Treating Patients Under Sas, Long-Term Administration of Xpro™ Has Been Safe and Well-Tolerated

ReutersApr 30 08:03 ET

Express News | INmune Bio Inc. Provides Update on Two Patients From the Phase 1B Alzheimer’s Disease Trial Who Continue to Receive Xpro™ Under Compassionate Use for Over Three Years

ReutersApr 30 08:00 ET

Express News | INmune Bio Completes First Cohort And Initiates Second Cohort Of Phase 1/2 Study Of INKmune Natural Killer Cell Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer

BenzingaApr 29 08:08 ET

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patien

GlobeNewswireApr 29 08:00 ET